A Pilot Study for the Evaluation of the Safety and Performance of a Combined OCT System (Hydra01)
A Prospective,Open Label,Non-randomized,Single-centre,Exploratory,Stratified Pilot Study for the Evaluation of the Safety and Performance of a Combined Coaxial Optical Coherence Tomography (OCT) System,to Image Diseases of the Posterior and Anterior Segment of the Eye
The novel Coaxial Optical Coherence Tomography (OCT) System is designed to visualize both structures of the retina and choroid.
The purpose of this research is the safety and evaluation of a combined coaxial optical coherence tomography (OCT) system, to image diseases of the posterior and anterior segment of the eye.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Background and Rationale:
Many posterior segment ocular diseases involve the retinal and choroidal vasculature. A new technology to noninvasively and simultaneously visualize vascular pathology is of utmost importance to reduce patient exposure to different diagnosis methods like e.g. fluorescence angiography. The novel Coaxial Optical Coherence Tomography (OCT) System is designed to visualize both structures of the retina and choroid.
Furthermore, it may be used to image other structures of the eye.
Objective(s):
The purpose of this research is the safety and evaluation of a combined coaxial optical coherence tomography (OCT) system, to image diseases of the posterior and anterior segment of the eye. This device may be useful for the early diagnosis and monitoring of a variety of diseases involving the eye, such as Glaucoma, Diabetic Retinopathy or Age-Related Macular Degeneration. Measurements are compared to normal controls.
Measurements and procedures:
After screening, all participants will undergo a scanning procedure on the same day.
Only one eye of each participant will be scanned with the investigational device. For patients, the eye showing the disease will be chosen, for healthy volunteers, the left or right eye will be scanned according to a randomisation list.
The image quality is rated by the investigator and an independent assessor on a VAS (visual analogue scale). A subgroup of each stratum will have a comparative measurement of the choroid thickness against a SS-OCT (swept-source-OCT) device (Topcon) and a retina thickness against the Spectralis data. The subgroup will consist of half planned sample size. The measurement is taken from one eye, ie. every second participant per stratum will be attributed to the thickness measurement subgroup. The endpoint is a true/false criterion on whether the measurement of the retina and choroid thickness was successful. The thickness is measured in μm. The measurement is considered a "success" if the value is no more than +/- 10% off the reference measurement.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Subjects with healthy eye, or has been diagnosed already with eye disease
- Patients > 18 years of age
- Informed Consent as documented by date and signature
Exclusion Criteria:
- Clinically significant concomitant disease that impair measurement
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, late stage Alzheimer disease, etc. of the participant,
- Subjects using implanted electronic medical devices (e.g. cochlear implant, pacemaker, defibrillator, infusion pump).
- Participation in another study with investigational drug within the 30 days preceding and during the present study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: Healthy subjects
One eye of each participant will be scanned with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
|
The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
|
|
Ander: Diseased groups
lf one eye is affected, this will be chosen.
lf both eyes are be affected, the eye with the severest symptoms will be chosen.
Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
|
The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
|
|
Ander: Diseased subgroups
Every second subject will be allocated to the subgroup.
|
The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Visual acuity (VA) after investigation
Tijdsspanne: Within 1 hour after investigation
|
Safety of the imaging investigation expressed as visual acuity before (baseline) and after imaging, and tolerability assessment questionnaire.
|
Within 1 hour after investigation
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Scan quality
Tijdsspanne: After completion of all measurement, an average of 2 years.
|
Comparing scan quality of investigational device to scan quality of a reference device, expressed as thickness of the retina and the thickness of the choroid
|
After completion of all measurement, an average of 2 years.
|
|
Procedural success
Tijdsspanne: After completion of all measurement, an average of 2 years.
|
Procedural success that is defined as: Image Quality of anterior and posterior eye structures
|
After completion of all measurement, an average of 2 years.
|
|
Procedural safety and comfort assessed by questionnaire
Tijdsspanne: Within 1 hour after investigation
|
Procedural comfort in the opinion of the patients assessed with a questionnaire
|
Within 1 hour after investigation
|
Medewerkers en onderzoekers
Onderzoekers
- Studie directeur: Hendrik PN Scholl, MD, University Hospital Basel, Dept. of Ophthalmology
- Hoofdonderzoeker: Pascal Hasler, MD, University Hospital Basel, Dept. of Ophthalmology
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- 085-HAP-2017-001
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Gezond
-
University of LeicesterNational Institute for Health Research, United KingdomVoltooidPatiënten met hartfalen en behouden ejectiefractie - HFpEF | Patiënten met hartfalen met verminderde ejectiefractie - HFrEF | Healthy Controls Group - Leeftijd en geslacht afgestemd
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesBeëindigdZiekte van Parkinson | Healthy Controls Group - Leeftijd en geslacht afgestemdFrankrijk
Klinische onderzoeken op combined Coaxial Optical Coherence Tomography (OCT) System
-
Notal Vision Ltd.Elman Retina GroupVoltooidDiabetisch macula-oedeem | AMD - Leeftijdsgebonden Macula DegeneratieVerenigde Staten